miR-223-5p Suppresses Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by Targeting E2F8.
Journal
Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097
Informations de publication
Date de publication:
05 Feb 2019
05 Feb 2019
Historique:
pubmed:
5
4
2018
medline:
21
3
2019
entrez:
5
4
2018
Statut:
ppublish
Résumé
miR-223-5p has been demonstrated to regulate the development and progression of various cancers, such as hepatocellular carcinoma, breast cancer, and gastric carcinoma. However, the role of miR-223-5p in non-small cell lung cancer (NSCLC) requires further investigation. In this study, we found that the expression of miR-223-5p was significantly downregulated in NSCLC tissues and cell lines. Moreover, the expression level of miR-223-5p is negatively correlated with the malignance of NSCLC. We found that overexpression of miR-223-5p remarkably suppressed the proliferation of NSCLC cells in vitro and in vivo. miR-223-5p overexpression also led to reduced migration and invasion in NSCLC cells. Mechanistically, we found that E2F8, a key transcription factor involved in many kinds of biological processes, was a direct target gene of miR-223-5p. Overexpression of miR-223-5p significantly decreased the mRNA and protein levels of E2F8 in NSCLC cells. We also showed that restoration of E2F8 rescued the proliferation, migration, and invasion of miR-223-5p-overexpressing NSCLC cells. Taken together, our findings demonstrated that miR-223-5p suppressed NSCLC progression through targeting E2F8.
Identifiants
pubmed: 29615147
doi: 10.3727/096504018X15219188894056
pmc: PMC7848460
doi:
Substances chimiques
E2F8 protein, human
0
MIRN223 microRNA, human
0
MicroRNAs
0
Repressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
261-268Références
Oncotarget. 2016 Apr 26;7(17):23757-71
pubmed: 26992224
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Int J Cancer. 2010 Mar 15;126(6):1283-90
pubmed: 19877123
Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):1-15
pubmed: 29275359
J Exp Clin Cancer Res. 2010 Nov 22;29:151
pubmed: 21092188
J Biol Chem. 2010 Dec 10;285(50):39551-63
pubmed: 20923760
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Cancer Med. 2016 Oct;5(10):2899-2908
pubmed: 27683099
Gastroenterology. 2008 Jul;135(1):257-69
pubmed: 18555017
Oncotarget. 2015 Jan 30;6(3):1740-9
pubmed: 25638153
Mol Cancer Res. 2011 Jul;9(7):824-33
pubmed: 21628394
Sci Rep. 2014 Dec 18;4:7546
pubmed: 25519054
Future Med Chem. 2013 Jun;5(9):983-5
pubmed: 23734680
Med Oncol. 2014 Nov;31(11):256
pubmed: 25270282
Neurosci Lett. 2010 May 26;476(1):18-22
pubmed: 20347935
J Natl Cancer Inst. 2015 Jun 18;107(9):
pubmed: 26089541
Cancer Sci. 2016 Jan;107(1):84-94
pubmed: 26509963
Genes Dev. 2006 Mar 1;20(5):515-24
pubmed: 16510870
Cancer Res. 2010 Jan 15;70(2):782-91
pubmed: 20068156
Med Oncol. 2014 Dec;31(12):298
pubmed: 25367852
Cancer Biol Ther. 2006 Jul;5(7):777-8
pubmed: 16880736
BMC Cancer. 2015 Jun 09;15:461
pubmed: 26055874
PLoS One. 2014 Jan 06;9(1):e84859
pubmed: 24400121
J Thorac Cardiovasc Surg. 2005 Jul;130(1):136-40
pubmed: 15999053
J Mol Diagn. 2013 Sep;15(5):695-705
pubmed: 23945108
J Exp Clin Cancer Res. 2017 Mar 7;36(1):40
pubmed: 28270228
Biomed Pharmacother. 2013 Jun;67(5):381-6
pubmed: 23601845
Blood. 2009 May 21;113(21):5237-45
pubmed: 19144983
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Lancet Oncol. 2007 Sep;8(9):784-96
pubmed: 17714993
J Biomed Sci. 2011 Mar 31;18:24
pubmed: 21453483
Br J Cancer. 2012 May 22;106(11):1826-32
pubmed: 22549179
J Integr Neurosci. 2016 Jun;15(2):205-21
pubmed: 27345028